Dabrafenib/Trametinib Combo Shows Long-Term Survival Benefit in Metastatic Melanoma
June 28th 2019First-line treatment with dabrafenib (Tafinlar) plus trametinib (Mekinist) demonstrated overall and progression-free long-term survival benefits in patients with BRAF-mutation positive melanoma.
Read More
FDA OKs Daratumumab Combo Regimen for New Multiple Myeloma Indication
June 28th 2019Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Read More
Federal Health Care Initiative Receives Pharmacy Support
June 27th 2019In a prepared statement, Pharmacy Quality Alliance (PQA) Chief Executive Officer Laura Cranston, RPh, said the organization applauds the initiatives outlined in “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First.”
Read More